An Evidence-based Methodology to Select Patients for Proton Therapy
and Clinical Validation.
Date & Time: Tuesday, 15 October 2019, 12.00pm to 2.00pm
Lunch: 12.00pm to 1.00pm | Lecture: 1.00pm to 2.00pm
Venue: National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610
Peter & Mary Fu Auditorium, Level 4
The relationship between 3-dimensional dose distributions and risks on radiation-induced side effects can be described
by Normal Tissue Complication Probability (NTCP) models. NTCP-models may contain only one dose-volume predictor
(dose metrics), but generally the performance of these model significantly improve when adding multiple other predictors
According to the model-based approach, next to outcome prediction, NTCP-models can be
applied for dose optimization, selecting the best radiation technology, plan adaptation and even technology validation.
For many side-effects, the risk may depend on more than one dose metrics to different organs at risk (OARs). To produce
treatment plans that eventually result in adequate target dose coverage with the lowest probability on side effects, dose
distributions to OARs should be translated into NTCP-profiles using NTCP-models (model-based dose optimization). For
the selection of the best treatment plan, or even for the selection of patients for more advanced radiation technologies,
like protons, information on NTCP-profiles next to dose profiles are essential to ultimately obtain the best clinical result.
Professor Johannes “Hans” A. Langendijk studied Medicine at the VU University in
Amsterdam. He was trained as a radiotherapist-oncologist at the Radiotherapeutic
Institute Limburg in Heerlen and Maasricht.
From 1997 to 2004, he worked as a radiotherapist-oncologist at the Radiotherapy
department of the VU Medical Center in Amsterdam. During that period he further
specialised in radiotherapy of tumors in the main neck area.
In October 2004, he worked as a professor / department head at the Radiotherapy
department of the University Medical Center Groningen. He is particularly interested
in head and neck oncology, prevention of radiation-induced complications and the
development of innovative methods for the development and clinical validation of new
radiotherapy techniques, such as proton therapy. Hans Langendijk holds various administrative positions at home and abroad,
including as chairman of the Landelijk Platform Protonentherapie (LPPT) [National Proton Therapy Platform] and within the European
Proton Therapy Platform (EPTN).
The NCCS' Humphrey Oei Distinguished Lecture Series aspire to be one of Singapore's leading
forums or intellectual inquiry and discussion in cancer and biological research. With eminent
scientists as a guest speakers, the series hopes to create an environment for exploration of ideas
and advances in cancer biology and medicine.
This lecture series is brought to you by the National Cancer Centre Singapore.
Seats are limited and online registration is required for admission.Doctors attending the lecture will be
awarded with one CME point.
For more information, please email us at email@example.com or contact us at 6352 0772 .
Scan the QR Code to register online! Or go to: http://bit.ly/2mm8pCP
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000